psyForce.ch Competitors

NeuroNexus is a global leader for innovative neural interface products and technologies to meet both current and upcoming needs in neuroscience research, neurosurgery, and neuromodulation. NeuroNexus powers neuroscience research through innovative neural probes, systems, and data analytics software. NeuroNexus probes include a full line of high-quality, customizable microelectrode arrays for electrophysiology and optogenetics research. NeuroNexus systems provide integrated plug-and-play solutions to support diverse neurophysiology experiments and workflows. The NeuroNexus data analytics software platform provides powerful, scalable, cross-platform analytical and visualization tools for managing and analyzing neurophysiological data -- from individual experiments to complex multi-investigator 'big data'.

Cognitive Consulting is a hybrid agency that blends art and science to provide customized solutions. We help our clients through every step of the marketing process, providing consultation, market research analysis, creative development, workshops, and marketing strategy implementation. Founded by Sharon Paik in 2014, Cognitive was created to help drive change across the dynamic healthcare sector, and to help organizations and manufacturers provide better patient care while improving their operations and brand management. Today, we apply our frameworks across various industries and categories. Our work is holistic as we harness the left (logical) and right (creative) sides of the brain to provide comprehensive output, always tailoring methodologies to meet our clients' specific organizational needs in order to deliver best-in-class strategies. Follow us across our channels: Twitter: @cog_consulting Instagram: cognitiveconsulting Facebook : http://on.fb.me/1mfG0Zf

NeuroVista Corporation was an early-stage medical device company pioneering new technologies that will revolutionize the management and treatment of epilepsy, a neurological condition affecting approximately 1% of the U.S. population—more than Parkinson's disease, multiple sclerosis and Lou Gehrig's disease combined.